Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
- Resource Type
- Source
- Kidney international 103(2), 391-402 (2022). doi:10.1016/j.kint.2022.09.017
Kidney international, Vol. 103, no. 2, p. 391-402 (2023) - Subject
gut-associated lymphoid tissue glucocorticoids Nephrology glomerular disease IgA nephropathy - Language
- ISSN
- 1523-1755